Parexel Launches Parexel Biotech Incubator 

Editor’s take: The biotech incubator aims to reach drug developers earlier in development, before clinical programs are formally structured.

Parexel, a global CRO, has launched the Parexel Biotech Incubator, a new initiative anchored at the company’s North Hills Innovation District global headquarters in Raleigh that connects early-stage therapeutics companies with the clinical and regulatory expertise to help advance their programs. The company has also entered a partnership with Cape Fear BioCapital to support early-stage innovation in collaboration with the venture community.

The Parexel Biotech Incubator is designed to support emerging therapeutics companies at a stage when development strategy is still taking shape. Participating companies will have access to Parexel’s clinical and regulatory expertise — including guidance on development planning, regulatory strategy and clinical trial design — alongside shared physical space that puts them in direct proximity to Parexel’s Raleigh-based team.

The incubator builds on Parexel’s broader commitment to investing in and fostering early-stage innovation alongside leading venture capital firms. Parexel has established collaborative relationships with leading venture firms as part of its strategy to advance and accelerate the next generation of therapeutics companies.

The partnership with Cape Fear BioCapital aims to bridge seed-stage investment and clinical development expertise. Cape Fear BioCapital focuses on advancing companies from early discovery through IND-readiness, and the alliance creates a direct connection between its portfolio companies and Parexel’s clinical and regulatory services.

“Reaching innovators at the earliest stages of their development journey, before clinical programs are formally structured, is where we can have the greatest impact. That is exactly what this initiative is designed to do,” said Peyton Howell, Chief Executive Officer of Parexel. “The incubator reflects the evolution of our support for the biotech community, connecting seed-stage investment to clinical development expertise at the stage when it matters most. It builds on our broader commitment to investing in early-stage innovation alongside leading venture firms, and our inaugural partnership with Cape Fear BioCapital deepens our roots in one of the most dynamic life sciences ecosystems in the country.”